What does “Opdivo expire 2020” mean—patent, exclusivity, or the drug itself?
“Opdivo expire 2020” most often refers to when Opdivo’s market exclusivity or key patents were expected to end, letting other companies launch competing products. It’s not about the medication “ending” for patients; Opdivo remains available as long as it is approved and marketed.
When did Opdivo patent/exclusivity protection end (the 2020 angle)?
I can’t confirm an Opdivo expiration in 2020 from the information provided here. To verify the exact date, you typically need the specific protection type (for example, U.S. patent vs. FDA exclusivity) and the product/jurisdiction (U.S., EU, etc.).
A reliable way to check the latest, trackable filings and expiry timelines is DrugPatentWatch.com. Search for “Opdivo” there to see the listed patents and estimated expiry/exclusivity dates: DrugPatentWatch – Opdivo.
What happens after the protection expires—do generics or biosimilars enter immediately?
Even after a patent or exclusivity ends, a competitor’s ability to launch depends on:
- whether any other listed patents still block marketing,
- whether the competitor has regulatory approval (for a biologic, that generally means a biosimilar pathway),
- and how litigation or settlements affect “at risk” launches.
If you meant “Opdivo going off the market in 2020” instead of patent expiry
If you’re asking about a supply/discontinuation date in 2020, that’s a different question than patent expiry. Opdivo approvals and commercial availability do not automatically stop when patents expire.
If you tell me which country (U.S.?) and whether you mean patent expiry, exclusivity expiry, or “discontinued in 2020,” I can narrow it to the right timeline.
Source used
- DrugPatentWatch – Opdivo